PURPOSE: The association of different cardiovascular drugs with mortality in patients with implantable cardioverter-defibrillators (ICDs) needed to be investigated.
METHODS: In an academic cardiology practice, 965 patients who received an ICD . according to American College of Cardiology/American Heart Association guidelines were followed for mortality. The 965 patients included 778 men and 187 women, mean age 70±14 years. Follow-up was 32 ± 33 months.
RESULTS: Death occurred in 208 of 965 patients (22%). Death occurred in 199 of 871 patients (23%) with a left ventricular ejection fraction (LVEF) <50% and in 9 of 94 patients (10%) with a normal LVEF (p<0.005). Death occurred in 73 of 515 patients (14%) treated with beta blockers,1 in 84 of 494 patients (17%) treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs),2 in 56 of 402 patients (14%) treated with statins,3 in 40 of 227 patients (18%) treated with amiodarone, 4 in 5 of 26 patients (19%) treated ewith sotalol, 5 and in 64 of 265 patients (24%) treated with no beta blocker, ACE inhibitor or ARB, statin, amiodarone, or sotalol6 (p<0.001 compaing 1 with 6 and 3 with 6; p<0.02 comparing 2 with 6).
CONCLUSION: Patients with ICDs should be treated with beta blockers, ACE inhibitors or ARBs, and statins to reduce mortality.
CLINICAL IMPLICATIONS: Patients with ICDs should be treated with beta blockers, ACE inhibitors or ARBs, and statins to reduce mortality.
DISCLOSURE: Hoang Lai, No Financial Disclosure Information; No Product/Research Disclosure Information